Our interpretation and recommendations on the recent regulatory guidance’s for Sponsors and CROs.
The statistical considerations for protocol amendments in the areas recommended by regulatory authorities using a case study.
Categories: Events
From this webinar you will learn: Insights derived from www.clinicaltrials.gov data to showcase the impact of COVID-19 on ongoing clinical trials by phase, recruitment status, sponsors and therapeutic area.
Our interpretation and recommendations on the recent regulatory guidance’s for Sponsors and CROs.
The statistical considerations for protocol amendments in the areas recommended by regulatory authorities using a case study.